Trial Profile
V260-027 Safety and Immunogenicity of RotaTeq in Elderly Subjects.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Rotavirus W179-9 vaccine (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 23 Oct 2011 Results for part I presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
- 24 Feb 2011 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
- 22 Apr 2010 Actual patient number changed from 260 to 66 as reported by ClinicalTrials.gov.